Foggia Prostate Cancer Risk Calculator 2.0: A Novel Risk Calculator including MRI and Bladder Outlet Obstruction Parameters to Reduce Unnecessary Biopsies.
PIRADS
bladder outlet obstruction
prostate cancer
risk calculator
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Jan 2023
26 Jan 2023
Historique:
received:
28
12
2022
revised:
16
01
2023
accepted:
18
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
Risk calculator (RC) combining PSA with other clinical information can help to better select patients at risk of prostate cancer (PCa) for prostate biopsy. The present study aimed to develop a new Pca RC, including MRI and bladder outlet obstruction parameters (BOOP). The ability of these parameters in predicting PCa and clinically significant PCa (csPCa: ISUP GG ≥ 2) was assessed by binary logistic regression. A total of 728 patients were included from two institutions. Of these, 395 (54.3%) had negative biopsies and 161 (22.11%) and 172 (23.6%) had a diagnosis of ISUP GG1 PCa and csPCa. The two RC ultimately included age, PSA, DRE, prostate volume (pVol), post-voided residual urinary volume (PVR), and PIRADS score. Regarding BOOP, higher prostate volumes (csPCa: OR 0.98, CI 0.97,0.99) and PVR ≥ 50 mL (csPCa: OR 0.27, CI 0.15, 0.47) were protective factors for the diagnosis of any PCa and csPCa. AUCs after internal validation were 0.78 (0.75, 0.82) and 0.82 (0.79, 0.86), respectively. Finally, decision curves analysis demonstrated higher benefit compared to the first-generation calculator and MRI alone. These novel RC based on MRI and BOOP may help to better select patient for prostate biopsy after prostate MRI.
Identifiants
pubmed: 36768769
pii: ijms24032449
doi: 10.3390/ijms24032449
pmc: PMC9917125
pii:
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
BJU Int. 2017 Dec;120(6):774-781
pubmed: 28207981
Front Oncol. 2021 May 20;11:693684
pubmed: 34094990
J Magn Reson Imaging. 2020 May;51(5):1556-1567
pubmed: 31750988
Anticancer Res. 2015 Apr;35(4):2175-82
pubmed: 25862875
JAMA Oncol. 2018 May 1;4(5):678-685
pubmed: 29470570
Med Ultrason. 2021 Aug 11;23(3):277-282
pubmed: 34113933
World J Urol. 2020 Oct;38(10):2555-2561
pubmed: 31907633
Eur Urol. 2020 Jan;77(1):78-94
pubmed: 31326219
Urology. 1994 Aug;44(2):199-205
pubmed: 7519380
Medicine (Baltimore). 2016 Feb;95(7):e2551
pubmed: 26886598
Front Oncol. 2018 Oct 16;8:438
pubmed: 30386737
Eur Urol. 2022 Nov;82(5):559-568
pubmed: 35963650
Urology. 2020 Dec;146:278-286
pubmed: 32956688
Cancers (Basel). 2021 Mar 31;13(7):
pubmed: 33807333
Radiology. 2020 Jul;296(1):76-84
pubmed: 32315265
Minerva Urol Nefrol. 2017 Oct;69(5):486-492
pubmed: 28124868
Ann Oncol. 2015 May;26(5):848-864
pubmed: 25403590
Front Oncol. 2021 Jan 08;10:603384
pubmed: 33489907
J Urol. 2020 Jul;204(1):82-90
pubmed: 31977261
Br J Cancer. 2012 Jan 31;106(3):436-9
pubmed: 22240787
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Eur Urol Open Sci. 2022 May 20;41:45-54
pubmed: 35813258
Urol Oncol. 2013 Jan;31(1):68-73
pubmed: 21396848
Eur Urol Oncol. 2021 Oct;4(5):731-739
pubmed: 34364829
Cancer Rep (Hoboken). 2021 Aug;4(4):e1357
pubmed: 33661541
Eur Urol Oncol. 2021 Oct;4(5):697-713
pubmed: 33358543